65 related articles for article (PubMed ID: 2382997)
1. CA-50 and CA-19.9 as tumour markers: which is preferable?
Maréchal F; Berthiot G; Legrand MG; Larbre H; Cattan A; Deltour G
Anticancer Res; 1990; 10(4):977-82. PubMed ID: 2382997
[TBL] [Abstract][Full Text] [Related]
2. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
[TBL] [Abstract][Full Text] [Related]
3. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
5. [CA-125 in non-ovarian benign and malignant pathology: study on 380 patients].
Marechal F; Berthiot G; Kritly T; Legrand MG; Deltour G; Cattan A
Bull Cancer; 1989; 76(7):697-706. PubMed ID: 2819261
[TBL] [Abstract][Full Text] [Related]
6. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
[TBL] [Abstract][Full Text] [Related]
7. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of serum TAC-41 in various digestive cancers].
Sato S; Yamanaka T; Kimura K
Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung.
Marechal F; Berthiot G; Deltour G
Anticancer Res; 1988; 8(4):677-80. PubMed ID: 3178158
[TBL] [Abstract][Full Text] [Related]
11. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers.
Kokociñska D; Jarzab B; Król R; Ziaja K; Szejbak K; Kuśmierski S
J Environ Pathol Toxicol Oncol; 1996; 15(2-4):283-7. PubMed ID: 9216823
[TBL] [Abstract][Full Text] [Related]
14. [Tag 72: a new tumor-associated antigen identified by a monoclonal antibody].
Piantino P; Fusaro A; Daziano E; Polloni R; Mosso R; Cacace G
Minerva Med; 1990 Nov; 81(11):765-7. PubMed ID: 2255410
[TBL] [Abstract][Full Text] [Related]
15. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract].
Heptner G; Domschke S; Schneider MU; Siegfried W; Domschke W
Dtsch Med Wochenschr; 1986 Mar; 111(10):374-8. PubMed ID: 2419074
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
19. [Comparative studies on the value of acute phase proteins and CA-125 for monitoring patients with ovarian cancer].
Kölbl H; Tatra G; Schieder K; Bieglmayer C
Strahlenther Onkol; 1988 Dec; 164(12):724-8. PubMed ID: 2462754
[TBL] [Abstract][Full Text] [Related]
20. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
